230 related articles for article (PubMed ID: 28555422)
1. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
Auer TA; Renovanz M; Marini F; Brockmann MA; Tanyildizi Y
J Neurooncol; 2017 Jul; 133(3):571-579. PubMed ID: 28555422
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
[TBL] [Abstract][Full Text] [Related]
3. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F
World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
[TBL] [Abstract][Full Text] [Related]
4. Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.
Eryılmaz MK; Mutlu H; Yalçin Müsri F; Salim DK; Tazegül G; Coşkun HŞ
J Oncol Pharm Pract; 2017 Jul; 23(5):392-395. PubMed ID: 27105898
[TBL] [Abstract][Full Text] [Related]
5. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.
Fraum TJ; Kreisl TN; Sul J; Fine HA; Iwamoto FM
J Neurooncol; 2011 Nov; 105(2):281-9. PubMed ID: 21603965
[TBL] [Abstract][Full Text] [Related]
6. The Safety of Bevacizumab Administered Shortly after Laser Interstitial Thermal Therapy in Glioblastoma: A Case Series.
Ali SC; Basil GW; Diaz RJ; Komotar RJ
World Neurosurg; 2018 Sep; 117():e588-e594. PubMed ID: 29933086
[TBL] [Abstract][Full Text] [Related]
7. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
8. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
[TBL] [Abstract][Full Text] [Related]
9. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
[TBL] [Abstract][Full Text] [Related]
10. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
Di Stefano AL; Labussiere M; Lombardi G; Eoli M; Bianchessi D; Pasqualetti F; Farina P; Cuzzubbo S; Gallego-Perez-Larraya J; Boisselier B; Ducray F; Cheneau C; Moglia A; Finocchiaro G; Marie Y; Rahimian A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
J Neurooncol; 2015 Feb; 121(3):499-504. PubMed ID: 25488073
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
[TBL] [Abstract][Full Text] [Related]
12. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Blumenthal DT; Mendel L; Bokstein F
J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
[TBL] [Abstract][Full Text] [Related]
13. The role of bevacizumab in the treatment of glioblastoma.
Diaz RJ; Ali S; Qadir MG; De La Fuente MI; Ivan ME; Komotar RJ
J Neurooncol; 2017 Jul; 133(3):455-467. PubMed ID: 28527008
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
15. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
[TBL] [Abstract][Full Text] [Related]
16. ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
Asenjo García B; Navarro Guirado F; Nagib Raya F; Vidal Denis M; Bravo Rodríguez F; Galán Montenegro P
Acta Radiol; 2020 Mar; 61(3):404-413. PubMed ID: 31357873
[No Abstract] [Full Text] [Related]
17. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.
Hattingen E; Bähr O; Rieger J; Blasel S; Steinbach J; Pilatus U
PLoS One; 2013; 8(3):e56439. PubMed ID: 23520454
[TBL] [Abstract][Full Text] [Related]
18. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
[TBL] [Abstract][Full Text] [Related]
19. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.
Choi SW; Shin H; Sa JK; Cho HJ; Koo H; Kong DS; Seol HJ; Nam DH
Cancer Med; 2018 May; 7(5):1774-1783. PubMed ID: 29573206
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
